All Press Releases Xinnate Receives FDA Rare Pediatric Disease Designation for TCP-25 for the Treatment of Epidermolysis Bullosa2 September, 2026 Xinnate Appoints Erik Kinnman as Chairman of the Board12 June, 2026 Xinnate receives FDA Fast Track Designation for TCP-25 for the Treatment of Epidermolysis Bullosa10 June, 2026 Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-2530 January, 2026 First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-2522 December, 2025 Xinnate Completes Oversubscribed Share Issue of SEK 38,5m18 December, 2025 Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa10 December, 2025
